Logo image of GMAB

GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis

NASDAQ:GMAB - Nasdaq - US3723032062 - ADR - Currency: USD

19.58  -1.22 (-5.87%)

After market: 19.58 0 (0%)

Fundamental Rating

7

GMAB gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making GMAB a very profitable company, without any liquidiy or solvency issues. GMAB has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes GMAB very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year GMAB was profitable.
In the past year GMAB had a positive cash flow from operations.
In the past 5 years GMAB has always been profitable.
Each year in the past 5 years GMAB had a positive operating cash flow.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

1.2 Ratios

GMAB's Return On Assets of 14.25% is amongst the best of the industry. GMAB outperforms 97.52% of its industry peers.
The Return On Equity of GMAB (17.77%) is better than 96.81% of its industry peers.
GMAB's Return On Invested Capital of 13.65% is amongst the best of the industry. GMAB outperforms 96.64% of its industry peers.
GMAB had an Average Return On Invested Capital over the past 3 years of 13.32%. This is in line with the industry average of 13.83%.
The 3 year average ROIC (13.32%) for GMAB is below the current ROIC(13.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 14.25%
ROE 17.77%
ROIC 13.65%
ROA(3y)14.15%
ROA(5y)15.85%
ROE(3y)15.69%
ROE(5y)17.48%
ROIC(3y)13.32%
ROIC(5y)15.82%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 5 10 15 20

1.3 Margins

GMAB has a Profit Margin of 29.01%. This is amongst the best in the industry. GMAB outperforms 98.05% of its industry peers.
GMAB's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 31.65%, GMAB belongs to the top of the industry, outperforming 98.94% of the companies in the same industry.
In the last couple of years the Operating Margin of GMAB has declined.
With an excellent Gross Margin value of 96.83%, GMAB belongs to the best of the industry, outperforming 96.81% of the companies in the same industry.
Industry RankSector Rank
OM 31.65%
PM (TTM) 29.01%
GM 96.83%
OM growth 3Y-19.72%
OM growth 5Y-6.68%
PM growth 3Y-17.51%
PM growth 5Y-11.5%
GM growth 3YN/A
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GMAB is creating value.
Compared to 1 year ago, GMAB has about the same amount of shares outstanding.
The number of shares outstanding for GMAB has been increased compared to 5 years ago.
The debt/assets ratio for GMAB is higher compared to a year ago.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B

2.2 Solvency

An Altman-Z score of 9.55 indicates that GMAB is not in any danger for bankruptcy at the moment.
The Altman-Z score of GMAB (9.55) is better than 86.02% of its industry peers.
GMAB has a debt to FCF ratio of 0.16. This is a very positive value and a sign of high solvency as it would only need 0.16 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.16, GMAB belongs to the best of the industry, outperforming 97.35% of the companies in the same industry.
A Debt/Equity ratio of 0.03 indicates that GMAB is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.03, GMAB is in line with its industry, outperforming 40.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.16
Altman-Z 9.55
ROIC/WACC2.09
WACC6.52%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B

2.3 Liquidity

A Current Ratio of 5.03 indicates that GMAB has no problem at all paying its short term obligations.
The Current ratio of GMAB (5.03) is comparable to the rest of the industry.
A Quick Ratio of 5.02 indicates that GMAB has no problem at all paying its short term obligations.
With a Quick ratio value of 5.02, GMAB perfoms like the industry average, outperforming 55.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.03
Quick Ratio 5.02
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.57% over the past year.
GMAB shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.70% yearly.
The Revenue has grown by 13.57% in the past year. This is quite good.
The Revenue has been growing by 40.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9.57%
EPS 3Y-2.95%
EPS 5Y22.7%
EPS Q2Q%-38.71%
Revenue 1Y (TTM)13.57%
Revenue growth 3Y17.67%
Revenue growth 5Y40.35%
Sales Q2Q%16.78%

3.2 Future

Based on estimates for the next years, GMAB will show a very strong growth in Earnings Per Share. The EPS will grow by 23.97% on average per year.
GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.31% yearly.
EPS Next Y30.61%
EPS Next 2Y22.39%
EPS Next 3Y23.56%
EPS Next 5Y23.97%
Revenue Next Year30.3%
Revenue Next 2Y23.74%
Revenue Next 3Y20.75%
Revenue Next 5Y18.31%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B 40B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

GMAB is valuated rather expensively with a Price/Earnings ratio of 19.01.
Based on the Price/Earnings ratio, GMAB is valued cheaply inside the industry as 95.58% of the companies are valued more expensively.
GMAB's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.39.
The Price/Forward Earnings ratio is 13.73, which indicates a correct valuation of GMAB.
Based on the Price/Forward Earnings ratio, GMAB is valued cheaply inside the industry as 95.93% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.37, GMAB is valued a bit cheaper.
Industry RankSector Rank
PE 19.01
Fwd PE 13.73
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GMAB is valued cheaply inside the industry as 97.35% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, GMAB is valued cheaply inside the industry as 97.52% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.53
EV/EBITDA 10.72
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

GMAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of GMAB may justify a higher PE ratio.
A more expensive valuation may be justified as GMAB's earnings are expected to grow with 23.56% in the coming years.
PEG (NY)0.62
PEG (5Y)0.84
EPS Next 2Y22.39%
EPS Next 3Y23.56%

More info and screens

0

5. Dividend

5.1 Amount

GMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENMAB A/S -SP ADR

NASDAQ:GMAB (1/28/2025, 5:24:06 PM)

After market: 19.58 0 (0%)

19.58

-1.22 (-5.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-12 2025-02-12/amc
Inst Owners45.28%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap12.44B
Analysts75.33
Price Target144.75 (639.27%)
Short Float %0.23%
Short Ratio1.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.35%
Min EPS beat(2)3.45%
Max EPS beat(2)67.24%
EPS beat(4)3
Avg EPS beat(4)16.67%
Min EPS beat(4)-58.69%
Max EPS beat(4)67.24%
EPS beat(8)5
Avg EPS beat(8)8.97%
EPS beat(12)9
Avg EPS beat(12)23.79%
EPS beat(16)12
Avg EPS beat(16)39.43%
Revenue beat(2)2
Avg Revenue beat(2)5.35%
Min Revenue beat(2)4.57%
Max Revenue beat(2)6.12%
Revenue beat(4)4
Avg Revenue beat(4)3.6%
Min Revenue beat(4)0.19%
Max Revenue beat(4)6.12%
Revenue beat(8)8
Avg Revenue beat(8)4.78%
Revenue beat(12)12
Avg Revenue beat(12)4.08%
Revenue beat(16)16
Avg Revenue beat(16)6.35%
PT rev (1m)0%
PT rev (3m)-0.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.59%
EPS NY rev (1m)0%
EPS NY rev (3m)2.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.12%
Revenue NY rev (1m)1.36%
Revenue NY rev (3m)1.25%
Valuation
Industry RankSector Rank
PE 19.01
Fwd PE 13.73
P/S 4.65
P/FCF 13.53
P/OCF 13.09
P/B 2.85
P/tB 5.36
EV/EBITDA 10.72
EPS(TTM)1.03
EY5.26%
EPS(NY)1.43
Fwd EY7.28%
FCF(TTM)1.45
FCFY7.39%
OCF(TTM)1.5
OCFY7.64%
SpS4.21
BVpS6.88
TBVpS3.65
PEG (NY)0.62
PEG (5Y)0.84
Profitability
Industry RankSector Rank
ROA 14.25%
ROE 17.77%
ROCE 17.53%
ROIC 13.65%
ROICexc 25.24%
ROICexgc 117.06%
OM 31.65%
PM (TTM) 29.01%
GM 96.83%
FCFM 34.35%
ROA(3y)14.15%
ROA(5y)15.85%
ROE(3y)15.69%
ROE(5y)17.48%
ROIC(3y)13.32%
ROIC(5y)15.82%
ROICexc(3y)77.56%
ROICexc(5y)85.03%
ROICexgc(3y)80.41%
ROICexgc(5y)91.41%
ROCE(3y)17.1%
ROCE(5y)20.32%
ROICexcg growth 3Y-13.79%
ROICexcg growth 5Y3.99%
ROICexc growth 3Y-11.73%
ROICexc growth 5Y9.55%
OM growth 3Y-19.72%
OM growth 5Y-6.68%
PM growth 3Y-17.51%
PM growth 5Y-11.5%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.16
Debt/EBITDA 0.15
Cap/Depr 74.58%
Cap/Sales 1.16%
Interest Coverage 200.13
Cash Conversion 106.92%
Profit Quality 118.41%
Current Ratio 5.03
Quick Ratio 5.02
Altman-Z 9.55
F-Score5
WACC6.52%
ROIC/WACC2.09
Cap/Depr(3y)105.55%
Cap/Depr(5y)103.01%
Cap/Sales(3y)2.49%
Cap/Sales(5y)2.51%
Profit Quality(3y)97.9%
Profit Quality(5y)95.71%
High Growth Momentum
Growth
EPS 1Y (TTM)9.57%
EPS 3Y-2.95%
EPS 5Y22.7%
EPS Q2Q%-38.71%
EPS Next Y30.61%
EPS Next 2Y22.39%
EPS Next 3Y23.56%
EPS Next 5Y23.97%
Revenue 1Y (TTM)13.57%
Revenue growth 3Y17.67%
Revenue growth 5Y40.35%
Sales Q2Q%16.78%
Revenue Next Year30.3%
Revenue Next 2Y23.74%
Revenue Next 3Y20.75%
Revenue Next 5Y18.31%
EBIT growth 1Y-8.06%
EBIT growth 3Y-5.54%
EBIT growth 5Y30.98%
EBIT Next Year23.79%
EBIT Next 3Y22.85%
EBIT Next 5Y25.22%
FCF growth 1Y231.72%
FCF growth 3Y4.57%
FCF growth 5Y67.11%
OCF growth 1Y201.48%
OCF growth 3Y4.68%
OCF growth 5Y48.71%